Compass PathwaysCMPS
About: Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Employees: 186
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
45% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 20
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
4% more funds holding
Funds holding: 116 [Q1] → 121 (+5) [Q2]
0.46% more ownership
Funds ownership: 42.81% [Q1] → 43.28% (+0.46%) [Q2]
22% less capital invested
Capital invested by funds: $228M [Q1] → $179M (-$49.6M) [Q2]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]
79% less call options, than puts
Call options by funds: $1.06M | Put options by funds: $4.99M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
RBC Capital Leonid Timashev 60% 1-year accuracy 21 / 35 met price target | 259%upside $23 | Outperform Reiterated | 10 Sept 2024 |
HC Wainwright & Co. Patrick Trucchio 39% 1-year accuracy 46 / 118 met price target | 1,772%upside $120 | Buy Reiterated | 23 Aug 2024 |
Canaccord Genuity Sumant Kulkarni 43% 1-year accuracy 10 / 23 met price target | 649%upside $48 | Buy Maintained | 2 Aug 2024 |
HC Wainwright & Co. Patrick Trucchio 39% 1-year accuracy 46 / 118 met price target | 1,772%upside $120 | Buy Reiterated | 31 Jul 2024 |
RBC Capital Leonid Timashev 60% 1-year accuracy 21 / 35 met price target | 259%upside $23 | Outperform Initiated | 23 Jul 2024 |
